Abstract FRI0761-HPR - 
Key: "Studies" refer to number of manuscripts, while "Estimates" relate to the number of countries within a manuscript that provided CWP prevalence estimates.
of socioeconomic position), GINI coefficient (measure of inequality), and latitude were added. Methodological reporting quality was assessed using the STROBE checklist [1] . Meta-analyses were conducted to determine global CWP prevalence, and individual-and contextual-dependent factors were evaluated using metaregression analyses.
Results: Thirty studies across 20 countries (630,654 participants) met the inclusion criteria. Studies varied in CWP diagnostic criteria, survey method, and reporting quality. Study CWP sample prevalence ranged from 1.4-24.0%, with CWP in men ranging from 1.1-15.3%, while in women it ranged from 1.7-22.1%. Estimated overall CWP prevalence was 9.4% (7.6-11.3%). By gender, the global CWP prevalence estimate in women was significantly higher than for men (10.9% [8.1-13 .7%] v 6.7% [4.5-8.8%], p≤0.01; Table) . A meta-regression of the contextual factors showed the HDI was related to CWP prevalence (p=0.002), while other measures such as survey type, methodological reporting quality and GINI index showed no significant effect. Conclusions: Globally CWP affects one in ten individuals within the general population, with women more likely to experience CWP than men. HDI was noted to be the socioeconomic factor related to CWP prevalence, with those in more developed countries having a lower CWP prevalence than those in less developed countries. There was a lack of data from countries with a lower socioeconomic position, and further CWP data in these areas can help determine if there are socioeconomic effects associated with CWP prevalence and can refine the CWP prevalence estimate. Background: Autoimmune inflammatory rheumatic diseases (AIRDs) are chronic in nature and common presentation involves the musculoskeletal system. Off lately, the researches have proved the strong association of tobacco in the development of the disease and increasing severity as well as reducing treatment efficacy. Therefore, awareness about the deleterious effect of tobacco and counselling to quit the same should be an imperative part of the patient education. Objectives: To assess the prevalence of tobacco use among patients with AIRDs and the effect of counselling on quitting tobacco. Methods: AIRDs patients attending the rheumatology clinic, willing to participate in the survey were enrolled in this study. Tobacco use was categorized as active [smoking or oral tobacco use] or passive (when the patient was exposed to tobacco smoke).All the information collected in pre-design form, which included demographic information and current status of tobacco use. They were also counselled about the methods of quitting tobacco and its importance and short-term follow-up details were recorded. 
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Background: There is limited information available describing the disease burden of primary Sjögren's Syndrome (pSS). Objectives: This retrospective cohort study aimed to provide a descriptive analysis of the clinical characteristics and disease burden of patients with pSS and describe their healthcare resource use and associated costs. Methods: This retrospective cohort study (HO-15-16077) was conducted in the US Truven MarketScan ® Commercial database. This database reports descriptive data from employees and their families, as covered by employer-sponsored private health insurance. The primary cohort comprised patients with ≥1 diagnosis of sicca syndrome prior to 1 January 2013, and continued enrolment for ≥24 months (1 January 2012 to 31 December 2013). Patients with any conditions mimicking sicca symptoms not due to SS were excluded, as were those with connective tissue disease that may suggest secondary SS. The 1:1 matched comparator population comprised subjects without a previous diagnosis of sicca syndrome (sicca-free). The primary objective was to describe the clinical characteristics and demographics of patients with pSS, including the proportion of patients with glandular versus extra-glandular disease. The secondary objective was to describe their healthcare costs and resource utilisation compared with sicca-free subjects. Results: There were 12,717 eligible patients in the primary cohort: the majority (86%) were female and the mean age was 51 years. Overall, 61% of patients had claims associated with extra-glandular disease manifestations. These patients experienced a higher disease burden with 41% reporting pain, fatigue and/or insomnia, compared with 12% of patients with glandular disease only who reported pain, fatigue and/or insomnia. Patients in the primary cohort incurred greater annual healthcare service costs (1.6 times greater for all causes and 1.5 times greater for pSS-related causes) and healthcare resource utilisation compared with the sicca-free comparator cohort. The largest difference in SS-related resource utilisation was in the number of office visits (primary cohort: 5.8 visits per patient; comparator cohort: 4.7 visits per patient). Patients with extra-glandular disease also incurred greater average annual costs and used more healthcare resources than patients with glandular disease only.
